Whitehawk Therapeutics
WHWK
33 hedge funds and large institutions have $324M invested in Whitehawk Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 19 closing their positions.
535% more capital invested
Capital invested by funds: $51M → $324M (+$273M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
49.05% more ownership
Funds ownership: 4.25% → 53.3% (+49%)
21% less funds holding
Funds holding: 42 → 33 (-9)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$46.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$46.6M |
| 3 |
VA
VR Adviser
New York
|
+$46.6M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$43.5M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.06M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.58M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$598K |
| 4 |
JIC
Johnson Investment Counsel
Cincinnati,
Ohio
|
-$542K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$353K |
WHWK Hedge Fund Activity: Q3 2021 in Review
33 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2021, worth a combined $324M — up 535% from $51M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of WHWK and 10 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $46.6M. The largest seller was Ikarian Capital, cutting an estimated $3.06M.
- 33 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2021, down from 42 in Q2 2021.
- Funds reported $324M of Whitehawk Therapeutics stock for Q3 2021, up 535% quarter-over-quarter.
- 10 funds opened new Whitehawk Therapeutics positions in Q3 2021 and 19 closed out, a net change of -9 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2021 was Acuta Capital Partners, an estimated $46.6M added.
- The largest Whitehawk Therapeutics seller in Q3 2021 was Ikarian Capital, an estimated $3.06M sold.
Based on aggregated 13F filings for Q3 2021.